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Abstract: Very few studies exist of legal interventions (national laws) for essential medicines as
part of universal health coverage in middle-income countries, or how the effect of these laws is
measured. This study aims to critically assess whether laws related to universal health coverage
use five objectives of public health law to promote medicines affordability and financing, and to
understand how access to medicines achieved through these laws is measured. This comparative
case study of five middle-income countries (Ecuador, Ghana, Philippines, South Africa, Ukraine) uses
a public health law framework to guide the content analysis of national laws and the scoping review
of empirical evidence for measuring access to medicines. Sixty laws were included. All countries
write into national law: (a) health equity objectives, (b) remedies for users/patients and sanctions
for some stakeholders, (c) economic policies and regulatory objectives for financing (except South
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Africa), pricing, and benefits selection (except South Africa), (d) information dissemination objectives
(ex. for medicines prices (except Ghana)), and (e) public health infrastructure. The 17 studies included
in the scoping review evaluate laws with economic policy and regulatory objectives (n = 14 articles),
health equity (n = 10), information dissemination (n = 3), infrastructure (n = 2), and sanctions (n = 1)
(not mutually exclusive). Cross-sectional descriptive designs (n = 8 articles) and time series analyses
(n = 5) were the most frequent designs. Change in patients’ spending on medicines was the most
frequent outcome measure (n = 5). Although legal interventions for pharmaceuticals in middle-income
countries commonly use all objectives of public health law, the intended and unintended effects of
economic policies and regulation are most frequently investigated.
Keywords: universal health coverage; universal health insurance; health insurance; access to
medicines; legislation; drug; insurance; pharmaceutical services; health services accessibility;
pharmaceutical policy; middle income country; essential medicines
1. Introduction
Universal access to essential medicines is an integral part of the Sustainable Development Goal
(SDG) 3 for health and SDG Target 3.8 on universal health coverage (UHC). Paying out of pocket
for medicines imposes a significant burden on people in low- and middle-income countries (LMICs),
where medicines account for up to 67% of all public and private health spending [1,2]. In these settings
50–90% of medicines expenses are paid out-of-pocket due to inadequate financial coverage for health
services or UHC [1,2]. UHC is defined by the World Health Organization (WHO) as “[E]nsuring
that all people have access to needed health services (including prevention, promotion, treatment,
rehabilitation and palliation) of sufficient quality to be effective while also ensuring that the use of
these services does not expose the user to financial hardship” [1].
It is also stated that “UHC can be accomplished only through the law” [3]. National legislation for
UHC establishes rules about the health system’s structure and function in order to provide access to
needed health services to the population while ensuring equity and financial coverage for the most
vulnerable [4]. Strengthening national legal frameworks to support access to health services has recently
featured prominently in global health debates [5–8]. The 2019 Lancet-O’Neill Institute Commission on
the Global Health and Law proposed three legal determinants of health [5]. One of those determinants
requires health laws to fulfil each element of UHC: (a) population coverage, (b) inclusion of services,
and (c) cost coverage [5].
UHC, and in particular the establishment of legal rules for the population, services, and cost
coverage elements of UHC, offers an opportunity to better regulate medicines for assured quality,
lower prices, and consistent availability, while promoting equitable service coverage [9]. To this end
we propose that five objectives of public health law, if properly embedded in law and implemented
in practice, can help attain universal access to essential medicines. The objectives of public health
law include: establishing public health infrastructure, applying economic policies (incentives and
disincentives) and regulation, transparency and information dissemination, promoting health equity,
remedies and sanctions [10]. These objectives offer different strategies in lawmakers’ toolboxes.
For example, legal interventions for medicines price control are ineffective if not properly resourced,
monitored, and enforced [11,12]. However, to our knowledge no study has investigated how national
UHC law employs these different objectives (separately or in concert) in relation to medicines
affordability and financing.
The intended and unintended effects of national UHC law on universal access to essential
medicines are a point of ongoing debate. Evidence shows that the introduction of health insurance
systems can improve access to pharmaceuticals and outcomes in LMIC [9,13]. A review of medicines
management in health insurance in LMICs found that studies tended to focus on strategies to
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influence prescribing, with little attention to strategies for medicines selection, procurement or use [9].
A pre-/post-intervention study suggests Chile’s universal system of health guarantees contributed to
better treatment of acute myocardial infarction (with pharmaceuticals, among other treatments) in
public hospitals and 1-year survival [13]. An interrupted time-series analysis of Thailand’s Universal
Coverage Scheme that expanded medicines coverage to the entire population resulted in increased sales
of essential and non-essential medicines for out-patient treatment of non-communicable diseases [14].
The latter study illustrates the potential for UHC-related laws to have unintended effects on medicines
prescribing, purchasing, or use. One prominent example of this is the former 15% mark-up on
medicines sales allowed at public hospitals in China [15]. This mark-up yielded important revenue
for public hospitals providing services for the Urban Employee Basic Medical Insurance scheme [15].
However, the mark-up policy also incentivised over-prescribing, particularly of antibiotics, injections,
and hormones [15,16].
Several key gaps in the literature impair a thorough understanding of the full range of effects of
national law on access to medicines in middle-income countries. First, there is a scarcity of data on
UHC-related laws as the intervention under study. Several reviews examine the role of laws, but also
“rules, financial and administrative orders made by governments, non-government organizations
[NGOs] or private insurers” on access to medicines [17]. The results in these reviews do not distinguish
between the different types of legal instruments used while they have important distinctions for
lawmakers and health systems. Legislation that must be adopted by elected lawmakers requires great
effort and time to negotiate and approve. The resulting law is usually more static (i.e., remains legally
binding throughout political and other changes unless it is repealed or reformed) than lower-level
orders (ex. those adopted by the executive branch such as the Ministry of Health), policies, or rules that
can be more easily revised or repealed by a government administration. In addition, previous studies
group together legal and guidance documents that are made by governments, NGOs, and private
insurers, while it is likely that only some of these are legally binding. Whether or not a document is
legally binding can affect how well it is implemented, monitored, and enforced in practice.
Second, there is little exploration of which measures and data sources in LMICs are capable of
and useful to assess the intentional and unintentional effects of law on access to medicines. One review
uses an open definition of outcome measures, while another defines outcome measures as only relating
to medicines use, healthcare utilisation, health outcomes, or costs [17,18].
Closely linked to the first two gaps, the third gap is the lack of knowledge about how the objectives
in public health law have an impact on traditional (i.e., those above) and other outcome measures of
access to medicines. This is a key challenge that lawmakers face. Lawmakers would benefit from more
evidence about how the objectives in their public health law toolkits have intentional and unintentional
impacts on medicines in the health system.
Fourth, the above gaps in knowledge persist in LMIC settings. Some review papers include data
from LMICs, while a minority are exclusively focused on LMICs [17,18]. The scarcity of published
evidence from LMICs is corroborated by several reviews [9,18,19].
This study aims to critically assess how UHC-related laws use the objectives of public health
law to promote medicines affordability and financing. This study also aims to describe how access to
medicines secured through the national law is measured. We propose that using a public health law
framework can offer a more holistic view of possible legal strategies to lawmakers seeking to promote
universal access to essential medicines as part of UHC in middle-income countries.
2. Materials and Methods
This five-country comparative case study includes a legal content analysis of national law related
to UHC and medicines and a scoping review of the evidence for measuring access to medicines secured
through the national law.
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2.1. Country Selection
We selected five middle-income countries (Ecuador, Ghana, the Philippines, South Africa, Ukraine)
that are at different stages of introducing a national health insurance system that covers people in
vulnerable situations. These countries also represent different WHO regions and legal families [20].
(See Table 1).
2.2. Legal Analysis
The legal mapping exercise collected national laws online between May–July 2020 if they concerned
any aspect of the pricing, affordability and/or financial coverage of pharmaceuticals for people in
vulnerable positions, guided by a previous study by Perehudoff et al. [21]. Laws included all relevant
legislative acts and regulations; where relevant, orders, instructions and rules implementing laws
were also included in order to keep the study manageable. All documents were included if they
related to the any of the five objectives of public health law in the context of medicines pricing and
affordability. Laws were excluded if they related to controlled medicines, traditional or alternative
medicines, the regulation of health professions, pharmaceutical advertising, medicines quality, safety,
and/or efficacy, or the rational use of medicines. Pharmaceutical policies were excluded from the formal
analysis because this study aims to capture the seldom-studied legal commitments and obligations
embedded in national law.
To validate the selection of laws, two authors collected laws for each country in iterative steps:
one author (KP) mapped national laws based on data collected from a previous study [21] while a
second author (AA, CED, ID, RS, FS), an expert in the national context, systematically verified (for
relevance) and retrieved or confirmed laws in their original language. Laws that were identified in the
scoping review were considered for inclusion if they met the above criteria.
Authors used national databases to identify laws currently in force (see complete list in
Supplementary Material S1). The laws were retrieved in their original language (English, Spanish,
Ukrainian). When laws were not published in English, co-authors (CED, ID) translated relevant legal
provisions from Spanish and Ukrainian to English. The analysts (KP, ID) scanned and confirmed
concepts, definitions, and context in the English translation and where needed, by consulting an
online translation from the original language and in liaison with the native speaking co-authors who
confirmed or corrected the translation. English-language translations of domestic constitutions were
sourced from the Constitute Project (constituteproject.org). See Supplementary Material S4 for the list
of national laws included in this study.
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Table 1. Overview of characteristics of the five middle-income countries.
Ecuador Ghana Philippines South Africa Ukraine
World region Americas Africa Western Pacific Africa Europe
Stage of UHC # Advanced Advanced Intermediate Early Advanced
Language of the national law database categorised by
WHO [20] Spanish English Filipino, English English
Ukrainian,
Russian, English
Population (millions), 2018 [22] 17.1 29.8 106.7 57.8 44.6
GNI per capita, Atlas method (current US$), 2018 [22] 6110 2130 3830 5750 2660
Legal system (categorised by WHO) [20] Civil CommonCustomary Civil, Common Civil, Common Civil
Total fertility rate (births per woman), 2018 [22] 2.4 3.9 2.6 2.4 1.3
Infant mortality rate (per 1000 live births), 2019 [22] 12.0 33.9 21.6 27.5 7.2
Domestic public expenditure on health expenditure as a
percent of general government expenditure (%), 2017 [23] 11.92 6.07 7.13 13.34 7.42
Domestic private health expenditure as a percent of total
health expenditure (%), 2017 [23] 46.64 52.03 65.50 44.39 54.30
Out-of-pocket payments as a percent of total health
expenditures (%), 2017 [23] 39.40 40.29 53.05 7.77 52.32
Total pharmaceutical sales as a percent of total health
expenditure (%), 2014 [24] 16.30 25.00 24.40 11.90 36.20
# Stages of UHC are defined as: Early = Legislative proposal for UHC covering vulnerable populations has not (yet) been adopted. Intermediate = Benefits package includes in-patient
medicines only. Advanced = Benefits package includes in- and out-patient medicines.
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Two authors trained in law (KP, ID) established definitions of the objectives of public health law
(called “categories” in Table 2, modified from Magnusson et al. [10]), which served as the analytical
framework. Authors (KP, ID) categorised the laws in three phases (1-laws from Ukraine to develop
and trial the categories and definitions in the framework; 2-laws from Ecuador to refine the framework;
3-laws from remaining three countries) using NVivo 12. Between each phase the coders discussed
coding differences and revised the coding definitions. The final framework was organised into five main
categories (Infrastructure, Economic policies and regulation, Information, Health equity, and Remedies
& sanctions).
Table 2. Five objectives of public health law (modified from Magnusson et al. [10]) in relation to
medicines affordability and financing. Legend: * Economic operators are defined as business entities
including but not limited to pharmaceutical manufacturers, distributors, importers, and wholesalers.
Public health infrastructure
These legal rules identify the public entitles (ex. Committees, agencies, authorities, bodies) responsible for
actions related to the selection of essential medicines, or the supply/procurement, IP management, pricing,
or reimbursement of medicines. This may include the selection criteria for members of these decision-making
bodies, their structure and organisation, roles and responsibilities, and other governance aspects [10].
Economic policies and regulation
These legal rules aim to incentivise and regulate the behaviours of government agencies, businesses, professionals
and individuals [10]. Economic policies and regulation may include regulations for financing health care and
insurance through public budgets (including pooling financing); the criteria for selecting and reviewing
pharmaceutical benefits under UHC, and the periodicity of revision; the procurement of pharmaceuticals by
public agencies; and policies and formulas for granting patents, data exclusivity, or intellectual property
flexibilities, and for identifying prohibited anti-competitive behaviour of economic actors.
Transparency and the provision of information
These legal rules aim to inform and educate third parties regarding a particular behaviour. In the context of
medicines financing and affordability, transparency encompasses information disclosure by all actors to
empower patients/users (to understand their medicines entitlements and compare prices), health professionals
(to provide the best care at the most affordable price), and public authorities (to compare, set, and negotiate
prices). Information for users or the public can include entitlements to a UHC benefits package, and how
health services are financed and organised.
Health equity
These legal rules aim to recognise the rights of individuals and the duties on States to protect and promote
those rights. Health equity may include the explicit recognition of: individuals’ rights to access essential
medicines and/or essential medical products/goods; the role of States to respect, protect, and fulfil individual
rights; Regulations for the financial coverage of poor people or people in vulnerable situations to protect
individuals and households from (catastrophic) out-of-pocket payments.
Remedies and sanctions
These legal rules aim to create mechanisms to hold pharmaceutical sector stakeholders to account for their
responsibilities and actions, particularly towards other objectives of public health law (i.e., providing
information, governing through committees and bodies, promoting health equity, implementing economic
incentives/disincentives and regulation). Remedies and sanctions may include: The availability of recourse for
complaints and remedies for users in case of an alleged rights violation in relation to UHC and
pharmaceuticals; Sanctioning the behaviour of health providers who are involved in the prescription,
dispensing, and/or use of medicines, that is contrary to good pharmaceutical care and/or medical ethics;
Sanctioning the behaviour of public authorities (including government officials and employees) that is
inconsistent with their legal and ethical obligations regarding pharmaceutical care; Sanctioning the behaviour
of economic operators * that is defined in legislation as undesirable.
2.3. Scoping Review
The search was conducted by three authors (NVA, DB, KP) based on peer-reviewed and grey
literature to identify evidence of how access to medicines achieved through the national public health
law is measured in our five study countries. This structured search was informed by the PRISMA-Sr
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guidelines [25]. The protocol search and selection strategy was piloted by two authors (KP, NVA),
revised, and finalised in May 2020.
Four bibliographic databases (Ovid Medline (1946–Present), Embase (1947–Present), Scopus,
and Web of Science) were searched. The search strategies were informed by a University of Toronto
librarian and further refined through piloting. The final search strategies for each database are available
in Supplementary Material S1. The last search was run on 15 May 2020.
The grey literature search included: (a) a structured Google search in English, Ukranian and
Spanish using the search terms “pharmaceutical, medicine, law + respective country”, “лiкaрськi
зaсоби, громaдське здоров’я, вплив[Medicines, public health impact, Ukraine]”, “Medicamentos
+ Ley + Impacto + Ecuador [Medicines + Law + Impact + Ecuador]”, and ““Política farmacéutica”
+ Ecuador [“Pharmaceutical Policy” + Ecuador]”; (b) a snowball search of the text and references of
relevant review articles [9,17–19,26–37]; (c) a snowball search of the text and references of relevant
WHO technical guidance documents [38,39]; and (d) crowdsourcing known publications from among
the authors.
The scoping review was designed using a Population-Concept-Context approach. The Population
is the five middle-income countries (Ecuador, Ghana, the Philippines, South Africa, Ukraine).
The database search included 10 countries: the five study countries plus Bangladesh, Colombia,
Indonesia, Jordan, and Turkey, which were excluded from this study at the full-text stage due to
insufficient access to primary data sources (national laws for Bangladesh, Colombia, and Turkey) and to
legal expertise to assist with the non-English analysis of national law (Indonesia, Jordan). The Concept
is essential medicines or pharmaceuticals that are defined by WHO as those used for disease prevention,
treatment, and control, and are applicable to most chronic and acute diseases [38–40]. The Context is
universal health coverage, which is defined in the introduction [20]. Our focus is on UHC schemes
that include people in vulnerable situations who are unlikely to be able to afford their medicines.
The inclusion criteria were: (a) study setting in one of the five countries selected; (b) a legal
intervention related to or with a conceivable impact on systems-level or patient-level measures of
access to medicines; (c) the outcome measures are related to any aspect of access to pharmaceuticals.
Eligible articles were not restricted by type of participants in the study countries nor by outcome
measure. Excluded articles studied the effects of private or regional/pilot micro insurance schemes
that are not governed by national UHC legislation, and analyses that preceded the adoption of a legal
intervention of interest (defined in the first part of this study). Review articles were excluded but
snowball searched for relevant literature (see grey literature search above).
English-language database citations were selected in four steps: (a) Automatic and manual
removal of duplicates in Mendeley (KP); (b) Title and abstract screening by two blinded reviewers
(NVA, DB) in Rayyan for inclusion and exclusion criteria; (c) Blinded full-text screening (NVA, DB) to
confirm the eligibility of the study; and (d) Snowball search of the references in eligible studies (NVA,
DB, KP). (See Figure 1) Disagreements on eligible articles were resolved through discussion.
One reviewer (NVA) extracted data using a template (see Supplementary Material S4) and the
second reviewer (KP, DB, CD) checked the results. No quality/risk of bias assessment was performed
on the selected articles. Variables collected from each eligible study included: design, law/legal
intervention, public health objectives of the legal intervention, study population (within the five study
countries), data source, main outcome measure(s), results. The evidence is presented in a narrative
format with the results grouped by the public health objective underlying the legal intervention studied.
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Figure 1. Flow diagram illustrating the selection process of included articles.
3. Results
3.1. How National Law Uses the Objectives of Public Health Law for Access to Medicines
Sixty laws and regulations were included in this study from five countries (Ecuador n = 13; Ghana
n = 7; Philippines n = 10; South Africa n = 7; Ukraine n = 23). All laws have been adopted except the
proposed National Health Insurance Bill in South Africa. All included laws are listed in Supplementary
Material S3.
Table 3 shows which objectives of public health law regarding medicines affordability and
financing are met in the laws of each country. Laws introducing economic policies and regulations,
measures for health equity, and remedies (for users/patients) are identified in each of the five
countries. Laws regarding information most often concern health providers’, public authorities’,
and economic operators’ responsibility to inform third parties about medicines prices, rather than about
pharmaceutical benefits. Sanctions for health providers, public authorities, and economic operators
are embedded in four countries.
The content of laws included in this study is summarised below. Where known, non-binding
policy or practice is mentioned in square parentheses for topics that were not addressed in law. See the
full country summaries in Supplementary Material S4.
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Table 3. Overview of the national laws in five middle-income countries that embed the objectives of
public health law for the affordability and financing of medicines. The laws on which this analysis is
based are listed in Supplementary Material S3. Legend: X = objective in law. P = objective proposed in
draft law. * = includes government officials and public employees.
Objectives of Public Health Law Ecuador Ghana Philippines South Africa Ukraine
Infrastructure & governance
(Decision making bodies for:)
Essential medicines selection X X
Medicines pricing X X X X
Benefits selection X X P
Procurement X X X P
IP management & competition X X X X
Economic policies & regulation
Public financing X X X X and P X
Pooled financing X X X P X
Medicines pricing X X X X X
Benefits selection X X X P X
Procurement X X X X
IP management & competition X X X X X
Information dissemination
(about Pricing/about UHC Benefits)
For users/public X/ /X X/ /P
By health providers X/ X/ X/ X/X
By public authorities X/ /X X/ X/P X/X
By economic operators X/ X/
Health equity
Individual rights X X X X X
State obligations X X X X X
Equitable financing X X X X and P X
Remedies & sanctions
Remedies for users/public X X X X and P X
For health providers X X X X
For public authorities * X X X X X
For economic operators X X X X
3.1.1. Infrastructure
A committee is established to select essential medicines which serves as the pharmaceutical
benefits plan (Ecuador, Ukraine). [A National Essential Medicines Committee is prescribed in policy
in Ghana, the Philippines and South Africa, rather than in legislation.] In addition, a body regulates
medicines prices (Ecuador, Philippines, South Africa, Ukraine). In the Philippines, an independent price
negotiation board negotiates with manufacturers on behalf of the DOH and PhilHealth. A committee
is established to allocate financial resources and advise on or review the health benefits plan (Ecuador,
Ghana, South Africa-proposed) and priority setting for benefits (South Africa-proposed). [In Ghana,
operational structures for priority setting are established and in the early stages of implementation.] A
centralised public procurement body is established (Ecuador, Ghana, Philippines).
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3.1.2. Information
Maximum retail prices of medicines in the private sector must be provided on medicines labels to
the public (Ecuador). In the Philippines, manufacturers, importers, distributors, wholesalers, traders,
and retailers must display the retail price on medicinal products that may not exceed the maximum
retail price. Manufacturers, importers, wholesalers, distributors or pharmacists in South Africa are
required by law to inform the public about the single exit price (SEP), availability, applicable pricing
system, supply chain, and fees charged by wholesalers, distributors, retailers, and other sellers (for
example, as a breakdown on the invoice to the patient). The Director-General may request any
information s/he may deem relevant from applicants for a SEP, including any pricing information.
Healthcare providers are obliged to inform patients about the medicines they can receive under
the medical guarantee program (Ukraine). [In South Africa health providers must also inform patients
about generics, but this duty was not identified in law.] Pharmaceutical workers may not conceal
information about lower priced medicines from consumers. (Ukraine)
Public authorities must publish a list of medicines’ prices that has been set (Ecuador); an electronic
catalogue of government procurement including prices (Ecuador); the generic names and corresponding
brand names of all medicines available on the market, annually in at least two newspapers (Philippines);
the trade names of reimbursable medicines, the amount of reimbursement and surcharge (if partially
reimbursed), and the retail price per package (Ukraine); the presence of a managed entry agreement,
including the INN, trade name, form and dose (Ukraine). Applications for medicines to be considered
on the Ukrainian National List of Essential Medicines are published on the Expert Committee’s website
after submission.
Members/participants receive information about the benefits package (Ghana, South Africa-proposed
legislation), the program of medical guarantees (Ukraine), and the funding of healthcare services (South
Africa-proposed).
3.1.3. Economic Policies & Regulation
In terms of public financing, the State is responsible for providing resources to the health sector
(Ecuador) and for medicines in the medical guarantee program (Ukraine). Funds from a variety of
sources (governmental, individual, employer, other) are pooled to support the social security for
peasants and fisherman, the general social security for employees in the formal economy and healthcare
(Ecuador), national health insurance (Ghana, Philippines, South Africa-proposed), health care (Ukraine).
The National Essential Medicines List serves as the basis for (Ghana) or the list of pharmaceutical
benefits (Ecuador). Health technology assessment has a role in evaluating pharmaceutical benefits
(South Africa-proposed). An explicit list of products excluded from a benefits package including
(non-exhaustive) products that are not included in the Formulary unless an exception applies
(South Africa-proposed), and products that are cost-ineffective ((Philippines, South Africa-proposed).
Pharmaceutical benefits must be regularly reviewed (Ecuador, Ghana).
Maximum retail prices apply to essential medicines (Ukraine) and in three scenarios (in Ecuador,
related to ‘strategic medicines’, competition failures, and sales above the fixed price and/or emergency
conditions). In the Philippines maximum retail prices also apply to medicines for the treatment of
chronic and life-threatening conditions, and price negotiation between health insurance purchasers and
manufacturers. A single exit price system (ceiling price) is implemented on all medicines registered
in South Africa for the private sector, which prohibits bonusing, rebates, or other incentive schemes.
This method of transparent pricing establishes appropriate dispensing fees for wholesalers/distributors,
pharmacists, and other dispensing health care professionals. A procurement price is established in
Ecuador’s public sector. Both countries have an electronic catalogue of government procurement prices.
Anti-competitive practices by dominant firms are prohibited; these include excessive pricing,
predatory pricing, margin squeeze, exclusionary acts on certain conditions, refusal to supply scarce
goods, buying up scarce supply of intermediate goods needed by a competitor, and refusing to grant
a competitor access to an essential facility when feasible to do so (South Africa), and forming a
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cartel, hoarding products, or profiteering (Philippines). To prevent excessive pricing in an emergency,
the prices of basic necessities including pharmaceuticals are automatically frozen at their prevailing
price (Philippines). Government use or compulsory licenses may be granted to remedy anticompetitive
practices by a patent holder, or in an emergency situation or in the public interest (all five countries).
Data exclusivity is granted for five years (Ecuador, Ukraine) and may be extended if certain conditions
are met by another six years (Ukraine).
3.1.4. Health Equity
The right to health is recognised in law (Ecuador, Ghana, Philippines, South Africa, Ukraine) and
specifically includes free of charge access to medicines (Ecuador), or a right to medical/health care
(Ghana, South Africa, Ukraine).
The State must create conditions for an effective medical service accessible to all citizens (Ukraine),
to realise health rights within available resources (South Africa), to make essential goods affordable
to all (Philippines), and to ensure the availability (Ukraine) and affordability (Ecuador) of essential
medicines. The State must guarantee specialised, timely and free-of-charge care to people suffering
from catastrophic or highly complex diseases (Ecuador). The President must report on steps taken
towards the realisation of the ‘right to good health’ (Ghana).
Medicines in the benefits plan are provided free of charge to all people attending public and
out-patient health facilities (Ecuador) to in-patients (Philippines, Ukraine). In Ukraine certain
categories of patients also have a right to free medicines, such as children with disabilities living in
particular regions and people with disabilities resulting from war, veterans, injured children and their
parents. Medicines are provided free of charge or at special prices for out-patients in case of diseases
(cardiovascular diseases, type II diabetes, bronchial asthma) (Ukraine).
A variety of exceptions and waivers for UHC contributions are in place to support the financial
coverage of vulnerable groups, including but not limited to ‘indigent’ members (Philippines, Ghana),
and others (Philippines, South Africa-proposed, Ukraine).
3.1.5. Remedies & Sanctions
A complaints procedure to resolve patients’/members’ grievances in the context of UHC must
be established in Ghana, the Philippines, and South Africa. In Ukraine, the State must establish
responsibility for rights violations in the field of healthcare, which requires the State and other relevant
entities to take measures to restore rights, protect citizens’ legitimate interests, and compensate for
damage. Consumer protection and remedies for violating the rights of users are provided in Ecuador’s
Constitution. Public service providers and producers of consumer goods are civilly and criminally
liable for inadequate provision of services or provision of a poor-quality product. The state can be
liable for civil damages due to negligence and carelessness in the provision of or deficiency in the
public services under its responsibility.
For health providers and economic operators, a range of penalties and/or sanctions are established
in relation to medicines pricing and price control. Penalties and sanctions may be applied for exceeding
the fixed price/price ceilings (to pharmaceutical manufacturers and medicines providers in Ecuador; to
any manufacturer, importer, trader, distributor, wholesaler, retailer or other entity in the Philippines;
anyone who contravenes the provisions for the single exit price in South Africa). In the Philippines
government officials and/or employees guilty of conspiring in these acts may also face criminal
penalties and/or administrative sanctions. Moreover, in the Philippines a penalty of imprisonment
and fines may be applied for manipulating prices by hoarding, profiteering or illegally combining or
forming a cartel, and other acts aiming to restrict the trade of medicines. In Ecuador, penalties and
sanctions may be applied to pharmaceutical manufacturers and medicines providers for exceeding
profit margins established by the national authority. Penalties may be applied to economic operators
guilty of anti-competitive behaviour (Ecuador, Philippines, South Africa).
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Sanctions and penalties can be given to health providers for failing to provide information about
medicines prices and substitution for lower-cost alternatives (established by law). In South Africa
pharmacists who fail to inform members of the public at point of dispensing about the benefits of
generic substitution, and doing generic substitution unless expressly forbidden to do so or the generic
price is higher than brand, or there is no substitute. Any person who contravenes the provisions for
generic substitution is liable for a fine or imprisonment. In Ecuador, dispensers (called ‘pharmaceutical
establishments’) can be sanctioned for failing to stock generic versions of brand name medicines
that appear in the National Table of Basic Medicines. Penalties also apply to pharmacies for failing
to provide consumers with access to the retail medicines prices of brand medicines and generic
equivalents sold, and for violating the provision in the Generic Medicines Act. In Ukraine, medical and
pharmaceutical workers are prohibited from and liable for advertising medicines, and for failing to
provide or providing inaccurate information about medicines with the same active substance available
at a lower price.
General sanctions for public authorities are embedded in UHC legislation; these may also
apply to the affordability and financing of pharmaceutical benefits. Disciplinary proceedings apply
to public servants for offences (i.e., improper demand or collection of unauthorised fees, Ghana).
Health institutions and health providers are liable for refusing to give benefits to PhilHealth members
entitled to them or charging patients for medicines covered by the program (Philippines). Legislation
establishes penalties for public servants in the UHC scheme (Ghana); describe corrupt acts in detail
in relation to public procurement (civil and administrative penalties in the Philippines); for false
information or representation towards the Fund, or use of money from Fund under false pretences
(South Africa- proposed); and for people guilty of violating legislation on the State financial guarantees
of medical care (Ukraine).
3.2. Measuring Access to Medicines Secured through National Law
A total of 17 studies were identified for inclusion in the review. The search of Ovid Medline, Embase,
Scopus, and Web of Science databases provided a total of 1327 citations (references). After including
articles located from the grey literature and adjusting for duplicates 961 articles remained. Of these,
862 studies were discarded because they did not meet the inclusion criteria and the full text of 99
studies was assessed for eligibility. Of these, 82 articles were excluded because the design did not
evaluate a legal intervention (n = 43), the study did not specifically examine pharmaceuticals (n = 7),
the setting was not in one of the five study countries (n = 13), the study concerned private insurance
or micro health insurance (n = 11), no full text was available (n = 6), or the articles were reviews or
summaries of original research already included in screening (n = 2). Seventeen studies were included
in the review. Figure 1 illustrates the inclusion process. Table 4 summarises the studies’ designs,
legal interventions, study populations and data sources, and main outcome measures and results.
Supplementary Material S2 presents the search results.
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Table 4. Results of the scoping review. Evaluations of legal interventions for medicines financing and affordability in five middle income countries.
Article Country Study Design Legal Intervention












Ecuadorian courts. This study
investigates the frequency of
successful claims, the clinical
eligibility of patients to receive
the medicines they claim,
the therapeutic monitoring of
court-ordered medicines,
and the potential budget
impact of court-ordered
medicines if extended to all









25 court claims (representing 33
patients with cancer) between
2012–2018 for government-funded
cancer medicines. Data was
collected from court decisions
published on the official website of
the Judicial System.
Data from trial registration pages
(National Library of Medicine,
clintrials.gov) were used to assess
whether the claimants fulfilled the
clinical trials eligibility criteria.
Therapeutic monitoring reports were
sourced from the National
Directorate of Medicines and
Medical Devices.
To estimate the potential budgetary
impact administrative statistics from
Ecuador were used. When they were
not available, extrapolations to the
Ecuadorian population were based
on data from www.Orpha.net
97% of court claims (n = 32/33 court
claims) involving the Ministry of Public
Health for government-funded cancer
medicines were granted between
2012–2018.
51.5% of patients did not meet the
eligibility criteria used in key clinical
trials demonstrating the efficacy of the
requested medicine.
Potential budgetary impact if medicine
universalised to all patients who need;




et al. 2019 [42] Ecuador
Cross-sectional qualitative
study to explore the perceived
effects of the 2008 health
reform implementation on
rural primary health care










Data was collected through focus
group discussions with health staff,
local health committee members,
village leaders, and community
health workers in a rural region of
the province of Esmeraldas.
Qualitative content analysis was
applied and Walt and Gilson’s model
for health policy analysis was used
to interpret the results.
Obstacles in communication about the
reform: 40–50% of villagers were aware
that medicines are now free of charge;
preconception that medicines in public
sector are of unreliable quality;
Increased demand for health care
services: Reports of patients requesting
medicines without being ill;
Availability after the reform: more free
medicines in the public system, but high
patient loads sometimes caused
competition for supply and shortages;
Financial effects for the population:
unconfirmed reports of free medicines
being sold (not allowed).
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with a time series analysis of
INN trends to assess whether
the AMP had succeeded in
fulfilling its objective to
provide more patients with
affordable medicines for
selected chronic diseases
(cardiovascular diseases, type 2
diabetes and bronchial asthma);
and to evaluate possible
uneven uptake of the
programme across oblasts
(geographic areas) and possible
explanatory factors
Law on State Financial
Guarantees of Health






Study population was the national
pharmaceutical market, and local
and national pharmaceutical
stakeholders.
Data sources were literature and
legal documents, quantitative data
from national and regional
authorities and private companies
about the pharmaceutical sector,
and structured qualitative interviews
with stakeholders.
Data was collected from
April-September 2018 for the period
prior to and following the
implementation of the 2017 law.
Accessibility: (a) >8 million Ukranians
enrolled in/covered by the AMP; (b)
6–28 pharmacies per 100,000 inhabitants
participated in the AMP, amounting to
40% of pharmacies in Ukraine; (c)
variable but increased consumption of
reimbursed medicines in all oblasts,
ranging from from 8% to 50% in
certain oblasts.
Affordability: (a) 85% average
reductions in patients’ co-payments; (b)
prices decreased in all except one
therapeutic area (bronchial asthma)
covered by AMP; (c) budget allocation
to AMP by the Ministry of Health was
21.8 million Eur in 2017 and 31 million
Eur in 2018.
Acceptability: No major complaints
reported by pharmacies (regarding
timely reimbursement by authorities)
and patients (except that they must
sometimes wait one day for
their medicines).
Efficiency: (a) INNs included in the
AMP were 21 by April 2017 and 23 by
end 2017; (b) Sales of medicines and
their market share increased markedly
after implementation. (c) No clear link
between the AMP and the recently
established Essential Medicines
committee, nor is there a formal process
for expanding the therapeutic areas
covered by AMP.
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4. Moodley
et al., 2019 [44] South Africa
Interrupted time series
analysis, examined the impact
of the in 2004 implemented
Single Exit Price (SEP)
intervention on private sector
price data from a basket of
generic medicines.










Price data were obtained from
pharmacy dispensing files,
claims data and other routinely
collected data for a basket of
medicines (50 originator and their
available generics). Data was
obtained for the period December
1999-December 2014, corresponding
to five years prior to the
implementation of the SEP
(1999–2003) and over the subsequent
ten years (2004–2014).
Three trends were observed with
different generics: (1) Medicine prices
prior to 2004 showed a year-on-year
steady rate of increase. The average rate
of increase before the regulation was
higher than the average rate of increase
after the regulation. (2) Medicine prices
were already decreasing prior to the
intervention in 2004, and after
intervention the medicine saw a price
reduction (n = 28 generic medicines); (3)
prices had a steady increase in price
between 1999 to 2004 with a steep drop
in 2004, which may be related to
competition or stock issues
(n = 3 generics).
5. Moodley
et al., 2019 [45] South Africa
Interrupted time series analysis
evaluating the impact of the in
2004 implemented Single Exit
Price (SEP) on the retail price of
a basket of
originator medicines.










Private sector retail price of fifty
originator medicines, based on
WHO/HAI basket of medicines.
Price data was obtained from
pharmacy dispensing files,
claims data, and other routinely
collected data. Data was obtained
for the period December
1999–December 2014.
“Most medicines investigated showed a
smaller yearly increase in price
compared to before regulations due to
the controlled pricing environment
introduced by Government.” Depending
on which list the product appeared
(global core, regional core,
supplementary), the average price
changed by 19.87% (SD 10.62%)–23.38%
(SD 12.43%).
6. Kanmiki




insurance claims to investigate









Ghana. 2003 (revised to




Revenue data for out-of-pocket
payments and health insurance
claims for unspecified medicines,
services and obstetric care.
Data was collected for the years
2010–2014 from public primary
healthcare facilities in seven districts
of the Upper East Region of
northern Ghana.
Between 2010–2014, out-of-pocket
payment for medications in primary
healthcare reduced by 62% and health
insurance claims for medicines increased
by 34% (2013) and 9% (2014).
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7. Durán et
al. 2019 [47] Ecuador
Interrupted time series analysis
investigated the impact of two











the core of the policy
being “the requirement
that any decision taken by
hospital DTCs regarding
selection of new drugs
must be confirmed by
the National
Medicines Directorate,
an administrative unit of




Patient dispensing data for
twenty-three targeted oncologic
medicines over five years
(2010–2014). Data is draw from
routinely collected data from the six
largest Ecuadorian cancer hospitals
(three private and three public).
“Transferring the responsibility to select
new drugs to hospital drug and
therapeutic committees produced an
increase in prescription intensity of
targeted oncologic drugs, mainly in the
private sector.” The second policy
intervention aimed to centralise these
decisions in a single body (while still
keeping the first level of decision
making in hospitals) reduced the
incidence of prescriptions of targeted
expensive oncologic medicines.
8. Dalinjong





whether the free maternal
health policy under the
National Health Insurance
Scheme (NHIS), [36]







Ghana. 2003 (revised to








406 women in the Kassena-Nankana




Data was collected through
structured questionnaires (with
women informants), 10 focus group
discussions (with women
informants), and in-depth interviews
(with health providers and
managers/directors). Data were
collected in March-August 2016.
Half of women interviewed reported
making direct out-of-pocket payments
for medicines during pregnancy care.
The average paid for medicines was
US$18.10 (SD US$34.40).
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9. Durán et
al., 2018 [49] Ecuador
Longitudinal study of hospital
dispensing data examining
utilization and expenditure









23 targeted oncologics, 43
chemotherapeutics, and 11 hormonal
medicines prescribed to 40,099
between 2010 and 2014. 60.3% of
patients were female.
Data from three public and three
private cancer centres in Ecuador,
comprising the six largest
Ecuadorian cancer hospitals in
2010–2014.
The proportion of patients using
targeted medicines doubled in the
period of 2010–2014, whilst the
utilization of chemotherapy showed a
downward trend, and the use of
hormonal therapy remained stable with
a dip in 2012.
Total expenditures on cancer drugs more
than doubled (by factor 2.3) in 5 years,
although the total number of patients
was rather stable through the period of
analysis. The rising pattern is driven by













childbirth under the free






Ghana. 2003 (revised to
Act 852 in 2012)
Implementing policy:
Free maternal care policy




353 women (mean age 27 years) who
gave birth in health facilities “in one
rural and poor area of Northern
Ghana; the Kassena-Nankana
municipality.” Data were collected in
March-August 2016.
91.8% of women incurred a mean
out-of-pocket payment for medicines
during childbirth of US$24.70.
11. Ashigbie
et al., 2016 [51] Ghana
Qualitative cross-sectional
study of key informants,
investigating the challenges of
medicines management in the
public and private sector under





Ghana. 2003 (revised to




Semi-structured interviews with 26
key informants purposively selected
from public and private sector
hospitals and standalone pharmacies
(including mission hospitals),
pharmaceutical supplies, and NHIS
district offices in the Eastern,
Greater Accra and Volta regions of
Ghana, interviewed between July
and August 2014.
Most informants “agreed that the
introduction of the NHIS has increased
access to and utilization of medicines by
removing cost barriers for patients.”
Common concerns include “delays in
receiving NHIS reimbursements,
and low reimbursement rates for
medicines which result in providers
asking patients to pay supplementary
fees.” Differences between private and
public sectors are weak separation of
prescribing and dispensing and limited
use of drugs and therapeutic committees
in the private sector,
the disproportionate effects of
unfavourable reimbursement prices for
medicines, and inadequate participation
of the private sector providers
(especially pharmacies and licensed
chemical sellers) in the NHIS.”
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12. Aryeetey
et al., 2016 [52] Ghana
Retrospective cross-sectional
study investigating the effect of
the National Health Insurance







Ghana. 2003 (revised to
Act 852 in 2012)
Economic policy &
regulations
Structured questionnaires and exit
interviews gauging the availability
of selected essential medicines in 34
mission facilities (hospitals, clinics,
specialist centres, and (primary)
health centres), grouped into the
three ecological zones: 12 coastal
(southern), 17 forest (middle) and 5
savannah (northern). Data were
collected for the periods 2003
and 2010.
Availability of essential medicines in
facilities generally improved after the
introduction of the NHIS in all three
ecological zones.
13. Espinosa
MV, 2016 [53] Ecuador
Pre-/post-intervention study of
medicines ceiling prices of
cardiovascular medicines after
the implementation of a price
control regulation.







marketed in Ecuador’s private sector
were included. Data was collected
from administrative datasets.
Pre-intervention sales prices were
derived from the Ecuadorian
Pharmacotherapeutic Formulary.
Post-intervention sales prices were
the ceiling prices set by the
Ecuadorian Technical Secretariat for
fixing prices.
There was no significant average change
in the ceiling price of the 364
cardiovascular medicines with prices
regulated under the Executive Decree no
400. However, the price of thiazides and
loop diuretics increased by US$0.018 per
unit (tablet) (p = 0.02), statins decreased
by US$0.21/unit (p = 0.001),
and angiotensin-converting enzyme
inhibitors decreased by US$0.10/unit (p
= 0.014) after the regulation took effect.
14. Kusi et
al., 2015 [54] Ghana
Cross-sectional representative
household survey investigating
the effect of the National
Health Insurance Scheme








Ghana. 2003 (revised to




Out of pocket health expenditures of
1082 household members who
reported sick in the last four weeks.
(449 were uninsured, 633 were
insured)
Data was collected through a
representative household survey
from three districts in Ghana
between February-April 2011.
The NHIS significantly decreased
OOPHE, but with respect to the cost of
prescribed drugs bought from outside
the facility, paradoxically insured
persons paid a higher amount (US$9.51)
than uninsured persons (US$7.08),
an observation for which the authors did
not have an explanation.
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and practices with respect to
the Cheaper Medicines Act
(CMA) and the Government
Mediated Access Price (GMAP)
list, assessing the impact and




and quality medicines act
of 2008 (“Cheaper
Medicines Act of 2008”).
Congress of
thePhilippines,” 2008.
Executive Order No 821 S,
“Prescribing the
maximum drug retail
prices for selected drugs
and medicines that
address diseases that
account for the leading






62 female respondents residing in
metro Manila from three
socio-economic classes (SECs)
participated in 9 focus group
discussions conducted in June 2013.
Participants were selected based on
the Philippine Marketing and
Opinion Research Society (MORES)
classification and on their being
household (HH) decision makers on
health matters
“Across all SECs, there is low
spontaneous awareness of the CMA
although many [respondents are]
spontaneously aware of the
Generics Act.”
“Across all SECs, mass media channels
are main sources of awareness and
information on the CMA. Government
doctors and health centres are poor
sources of information on the CMA but
are very good sources of information
and advice on generics especially among
the lowest SEC. Private doctors are poor
sources of information on the CMA
and generics.”
“Respondents across all SECs have not
noticed the GMAP price list in
drugstores. They also have not noticed
price reductions in branded
drugs-possibly because GMAP does not





investigating the impacts of the
maximum drug retail pricing
(MDRP) policy and the
government-mediated access
prices (GMAP) policy,
flowing from the “Cheaper
Medicines Act” of 2008,
on selected medicines




and quality medicines act
of 2008 (“Cheaper
Medicines Act of 2008”).
Congress of the
Philippines,” 2008.
Executive Order No 821 S,
“Prescribing the
maximum drug retail
prices for selected drugs
and medicines that
address diseases that
account for the leading





Price data of eleven selected
medicine molecules which were
placed under MDRP/GMAP listing.
Data was collected through
independent surveys conducted by
IMS Health Philippines from a
stratified sample of 600 retail
medicine stores in 2009 and 2011
each. Price data were obtained using
a mystery shopper approach.
Ten of the 11 medicines significantly
decreased in mean price by being listed
as MDRP/GMAP reference drugs.
However, the author concluded that the
number of MDRP/GMAP listed
medicines was very limited compared to
the total list of essential medicines and
the polices may not have had a tangible
effect yet.
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17. Nguyen
et al., 2011 [57] Ghana
Cross-sectional study
evaluating the impact of the
National Health Insurance
Scheme (NHIS) on households’
out-of-pocket spending and
catastrophic health





Ghana. 2003 (revised to




Health expenditure data from a
survey of 2500 households (11,617
persons in total, of which 6718 are
NHIS non-members and 4899 are
NHIS members). The survey was
conducted in two rural districts,
Nkoranza and Offinso,
in September–October 2007.
NHIS members incurred out-of-pocket
medicine payments that equaled 73% of
those incurred by NHIS non-members.
A ‘not trivial’ portion of these
out-of-pocket payments were for
medicines (among other services) that
should be covered by insurance.
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Study settings were Ghana (n studies = 7); Ecuador (n = 5); the Philippines and South Africa
(n = 2 each); and the Ukraine (n = 1). All studies were observational. The main study designs were
(not mutually exclusive) cross-sectional descriptive (n = 8), time series analyses (n = 5), convergent
parallel mixed methods (n = 2), or longitudinal, pre-post-intervention, or cohort (n = 1 each).
The main outcome measures were (not mutually exclusive) a change in out-of-pocket spending,
or cost of or co-payment for medicines for the patient (n = 5), medicines utilisation (n = 3), private sector
retail price (n = 2) or ceiling price (n = 2), hospital expenditure on medicines (n = 1), medicines
availability in mission facilities (n = 1), INNs included in the reimbursement system (n = 1), medicines
sales volumes and market shares (n = 1), number of patients covered by reimbursement system (n = 1),
number of pharmacies enrolled in reimbursement system (n = 1), budget allocation by Ministry of
Health to pharmaceutical reimbursement (n = 1), potential budget impact of court-ordered medicines
if the decision was extended to all eligible patients (n = 1), and a relationship between the Essential
Medicines Committee and the process for expanding the reimbursement list (n = 1), and the frequency
of successful court claims for access to publicly funded medicines (n = 1). Self-reported outcome
measures included household knowledge, attitudes, and practices with regards to medicines (price)
regulation (n = 1); opinions and beliefs about change in demand for and availability of medicines,
and awareness of medicines coverage (n = 1); and major complaints reported by pharmaceutical sector
stakeholders (n = 2).
The main legal interventions were concerning framework and implementing legislation for
national health insurance (Ghana n = 7 studies; Ukraine n = 1), of which two studies were related to
free maternal health care in Ghana. Other legal interventions related to constitutional rights to access
medicines (Ecuador n = 3), medicines price regulations (South Africa n = 2; Philippines n = 2), and a
decree allowing hospital drug and therapeutic committees to select and procure drugs non-essential
medicines (Ecuador n = 1). Studies investigating the effects of legal interventions can be primarily
characterised (not mutually exclusive) as having economic policy and regulatory objectives (n = 14),
health equity objectives (n = 10), information dissemination objectives (n = 3), infrastructure objectives
(n = 2), and remedies and sanctions (n = 1).
4. Discussion
In the five MICs we studied, laws in most countries embed public health infrastructure, such as
essential medicines or benefits selection committees; economic policies for and regulation of public
financing, pooled financing, medicines pricing, and benefits selection; information dissemination,
such as about medicines prices; health equity including rights, obligations, and equitable financing;
and remedies for users/patients and sanctions for stakeholders. In the national laws we analysed,
economic policy and regulatory objectives frequently appeared together with informational and health
equity measures. Most evaluations of legal interventions investigate outcomes related to economic
policies and regulations and health equity, most commonly a measure of patients’ out-of-pocket
spending on medicines, or medicines cost or patient co-payment for medicines. Few studies evaluated
legal interventions for information dissemination (ex. on patient knowledge, attitudes and behaviours
towards lower-cost generics), for public health infrastructure (ex. centralised and decentralised
medicines selection committees on medicines utilisation), and for remedies or sanctions. This study
offers an overview for law makers in middle-income countries about what is known about the effects of
those public health law for medicines financing and affordability, and how this evidence was measured.
4.1. Public Health Law Analysis
Public health infrastructure, such as establishing decision making bodies related to medicines
affordability and financing are formalised in different ways. In this study we observed that some
civil law countries (Ecuador, Ukraine) prescribe the structure, function, and responsibilities of these
bodies in national law. Common law countries (Ghana, Philippines, South Africa) construct these
types of public health infrastructure in policy rather than law [58]. For example, the national
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pharmaceutical policy in Ghana establishes the National Medicines Selection Committee and the
National Medicines Price Committee; the latter committee sets prices for all reimbursed medicines [59].
Investigating optimal governance structures and models (centralisation vs. decentralisation) is an
important component of the effective implementation of laws by the competent committees, authorities,
and bodies. One study from Ecuador examined the impact of policy changes allowing hospital drug
and therapeutic committees to select and procure non-essential cancer medicines on their utilisation in
hospitals [35]. Another study from the Ukraine reported that there was no clear relationship between
the Committee recently established to select essential medicines and the decision making process to
expand the reimbursement list [31]. Further studies should be undertaken to evaluate the effect of
changes in public health infrastructure and the relationships between different bodies related to the
selection and use of medicines.
In our study, most outcome measures relate to economic policies and regulation such as the cost
of medicines for patients. Future research should also focus on other types of outcome measures to
reveal how different components of laws function in practice. Each country we studied has legal rules
requiring public financing for a selection of pharmaceuticals, yet the effects of this legal intervention
are not assessed in practice. Future research could quantify the level of government budget allocations
(as was done in Ukraine) and/or actual spending on essential medicines provision/pharmaceutical
benefits, or the real-time availability in health facilities of pharmaceuticals to which UHC members are
entitled (also related to benefits selection).
Transparency and the provision of information is a key objective of public health law. In the
context of medicines financing and affordability, transparency encompasses information disclosure
by all actors to empower patients/users (to understand their medicines entitlements and compare
prices), health professionals (to provide the best care at the most affordable price), and public
authorities (to compare, set, and negotiate prices). In this study national law embeds more obligations
for pharmaceutical sector stakeholders to provide information about medicines pricing than about
pharmaceutical benefits. Future research should investigate the effectiveness of legal interventions at
enhancing patient-level knowledge about their medicine’s entitlements and lower-priced alternatives.
Further studies should also explore which conditions and factors facilitate health providers,
public authorities, and economic operators to provide the information about medicines pricing
and benefits that they are required to [58].
Health equity objectives, and specifically state obligations and individual rights, were identified in
the laws of all countries in our study. Only one study examined the effect of a constitutional entitlement
on the rate of medicines utilization in hospital [37]. Future research should consistently disaggregate
outcome measures (i.e., patient prices, out-of-pocket payments) by wealth quintile or other measure to
assess equitable financing. One example of this is the study from Ukraine that disaggregated many
indicators (ex. number of pharmacies, proportion of population benefitting from medicines access,
increase in consumption of medicines after legal intervention), by geographic region in the country [31].
Laws aiming to provide remedies and sanctions for rights violations are important for holding
pharmaceutical sector stakeholders to account for their responsibilities and actions, particularly towards
other objectives of public health law (i.e., providing information, governing through committees and
bodies, promoting health equity, implementing economic incentives/disincentives and regulation).
We identified one study that reported no informal complaints from pharmaceutical sector actors,
and a second study that investigated formal court claims by patients for access to publicly funded
medicines [29,31]. Future research should investigate two types of outcomes. Intermediate outcomes
assess whether and how processes for seeking remedies and sanctions are used. These outcomes
could include the number of patients/users who have filed a complaint for an alleged violation of
their rights to available and affordable pharmaceutical benefits; number of healthcare providers or
economic operators who have been reported for alleged violations such as failing to provide required
price information or engaging in anti-competitive behaviour. End outcomes assess the final result of
remedial action and/or sanctions, and these outcome measures can be paired with measures of other
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public health law objectives (i.e., trends in medicines prices or patients’ out-of-pocket payments) to
build a more complete picture of how laws are influencing access to medicines in practice. Possible
end outcomes could include the number and nature of sanctions actually applied to health providers
and economic operators (i.e., fines for anticompetitive behaviour). Another end outcome could be the
number and nature of administrative decisions made on patients’ complaints. Administrative and
quasi-judicial remedies available to patients at the level of health facilities could help redress rights
violations and avoid or ease the pressure on the judicial system in countries where patients litigate
for medicines.
4.2. Role of Pharmaceutical Policy
Laws about pharmaceuticals are neither adopted nor implemented in a vacuum. They are
influenced by and have an effect on domestic pharmaceutical policies and practices. It is therefore
surprising that few papers we screened describe the legal environment (with regards to medicines
access) in which the study takes place. A survey of 55 and 56 low- and middle-income countries
found that national pharmaceutical policies are associated with lower antibiotic use and better use of
medicines (based on a quality use of medicines composite index), respectively [60,61].
Pharmaceutical policies, although not legally binding, are governance instruments. They may
direct and instruct certain priorities and actions in the national pharmaceutical sector, including
the adoption or reform of legislation [38,62]. In this way policies can have direct and indirect
effects on systems-level and/or patient-level access to medicines [40,60,62]. Pharmaceutical policy
in some countries creates a supportive environment for the introduction of legislation for economic
incentives/disincentives and regulation. For example, Ghana’s 3rd National Medicines Policy (2017)
recommends a mix of interventions to achieve lower medicines prices. In 2017, legislation was adopted
to exempt selected pharmaceutical raw materials and active pharmaceutical ingredients as well as
selected imported finished pharmaceutical products from Value Added Tax (VAT). At the time of
adoption, private sector stakeholders projected that the VAT exemptions on selected medicines would
result in a 30% reduction in the NHIS tariffs on medicines [59,60,62].
4.3. Policy Implications
We argue that a greater understanding is needed of the tangible effects on access to medicines of
adopting, implementing, and enforcing specific legal concepts and texts on the path towards UHC.
Most existing guidance publications about pharmaceuticals for law makers regard pharmaceutical
regulation (i.e., safety, quality, and effectiveness) and clinical trials, and high-level pharmaceutical
sector policies (with little focus on UHC) [63–65]. Recent WHO guidance documents on pharmaceutical
pricing strategies identify the need for legislation as ‘infrastructure’ to implement policies (ex. for pooled
procurement, price transparency) [38,39,66]. However, these documents lack an analysis of the types of
legal instruments, the legal concepts, examples and approaches to legislate for these interventions [38,39].
Overall, our analytical approach using a public health law framework can inform other
governments in analysing legal reforms to identify strengths and gaps with respect to medicines
financing and affordability.
To this end, our study includes one proposed legal act for National Health Insurance in South
Africa. Our analysis reveals key strengths of this proposed legislation, being the establishment of
committees responsible for determining pricing and medicines benefits, a range of economic policies
and regulation for public financing, pooled financing, the selection of benefits, and equitable financing;
the provision of information about pharmaceutical benefits by public authorities to patients; and the
availability of remedies for users/patients and sanctions for public authorities. Our analysis shows
that, in addition to the above measures, the proposed Act could embed a duty and mechanisms for
public authorities to monitor medicines affordability and financing, economic incentives for medicines
procurement in the context of national health insurance, and the dissemination of pricing information
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by pharmaceutical sector stakeholders. Similar analyses could be made for other MICs introducing
legislation for UHC, such as the draft National Health Protection Act in Bangladesh.
4.4. Strengths & Limitations
The key strengths of this study are the diversity of middle-income countries and national contexts
(from early to advanced UHC systems), which provide insights from different types of legal systems.
Our study uses law as a primary source (rather than a key informant’s interpretation of the law/policy,
as is done in other studies). In addition, this study interprets the findings with the benefit of insights
of co-authors who are local pharmaceutical policy experts. Applying a public health law framework
takes a broad view of all possible legal strategies for medicines financing and affordability (from
infrastructure to sanctions), not only the substantive pricing and financing policies that most other
studies focus on. Finally, this research highlights the empirical effects of known legal interventions,
which is of interest to pharmaceutical policy and regulation researchers designing and conducting
such studies, and legal scholars seeking to understand how the impact of laws can be measured.
Our study has several limitations. The overall aim of our study was not to produce a detailed
description of the entire pharmaceutical policy landscape of each country. Therefore, aspects of
medicines financing and affordability that are addressed in national pharmaceutical policies are only
briefly described in this article.
Analyses of federal legislation excludes potentially important legal norms, developments,
and contextual nuances at the regional/state/provincial, or municipal levels, which could play a
role in countries such as the Philippines. From this study it is not possible to determine whether and
how each federal law is implemented in practice. We enhance the reliability of our legal mapping by
using explicit search terms, an automated and manual search, and classification of legal text and two
coders who used a framework with categories and definitions.
This study includes relatively few evaluations of UHC and related legal reforms for medicines
financing and affordability considering the sweeping UHC reforms that most countries in our sample
have embarked on. In general, our screening process revealed a reasonable number of studies
investigating the effect of a legal intervention on access to healthcare in general, but few specifically
disaggregated healthcare into its subcomponents (i.e., medicines, services, etc.), thereby precluding us
from generalising the effects on access to medicines specifically.
4.5. Future Research
Future studies of public health law interventions should prioritise robust study designs such
as interrupted time series analysis and natural policy experiments from which conclusions about a
causal relationship between a legal instrument and an indicator of access to medicines can be drawn.
Theory-based qualitative studies can also be useful to understand the context, facilitators, and barriers
to legal implementation and enforcement. Pharmaceutical law and policy research should draw from
a range of disciplines including political science, economics, clinical medicine, public health, law,
sociology, and anthropology.
Second, future studies should diversify the outcome measures used (including by investigating
intermediate and end outcomes) and match them to the public health objectives of legislation.
In addition to the above examples, we also propose investigating clinical and social outcomes (i.e.,
ability to pay one’s bills) in patients who receive free-of-charge access to pharmaceutical benefits
(related to health equity) [67].
Third, future research should investigate the process and pace of UHC reform with regards to
pharmaceuticals, specifically to understand how trust and buy-in should be built among pharmaceutical
sector stakeholders in order to design and implement proposed UHC legislation. Legislation that does
not enjoy broad stakeholder support will face many challenges in implementation.
Fourth, future research could explore the effect of international law and trade and investment
treaties on domestic UHC and measures of access to medicines. Changes in international law or
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a State’s ratification of international law (and therefore having an obligation to bring national law,
policy and practice in line with international norms) could have an effect on essential medicines [68].
Fifth, pharmaceutical sector stakeholders such as pharmaceutical and health insurance companies,
and health providers, may introduce sector-specific rules and policies that affect measures of access
to medicines. Industry initiatives can also have a significant impact on access to particular products
or classes of medicines, such as for diabetes and Direct-Acting Antivirals for treating the hepatitis C
virus [69–72]. Therefore, the interaction between UHC legislation and industry’s access policies is an
important avenue for future research.
5. Conclusions
Five objectives of public health law were identified in national law for medicines financing
and affordability in our five middle-income countries. Empirical evaluations of national law were
mostly designed to evaluate economic policies and regulation, while scarcely evaluating the other
four objectives of public health law (public health infrastructure, information, health equity, remedies
and sanctions). Although laws for access to medicines are frequently adopted by law makers, the full
range of their intentional and unintentional effects on medicines access in health systems is under
studied. Adopting laws for all components of public health law and understanding their effectiveness
at promoting universal access to medicines, is important to enforce UHC reforms. Further studies are
required to understand the range of legal interventions for UHC and pharmaceuticals and to measure
the spectrum of possible effects on access to medicines in middle-income countries. This analysis of
legal interventions can provide future direction to design and analyse legal action and reforms initiated
for improved access to medicines.
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